Aim To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared with no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. Design Cost-effectiveness analysis from a National Health Service (NHS)/health-provider perspective, utilizing a dynamic transmission model of HCV infection and disease progression, calibrated using city-specific surveillance and survey data, and primary data collection on NSP costs. The effectiveness of NSPs preventing HCV acquisition was based on empirical evidence. Setting and participants UK settings with different chronic HCV prevalence among people who inject drugs (PWID): Dundee (26%), Walsall (18%) and Bristol (45%)
INTRODUCTION
Hepatitis C virus (HCV) is a global public health issue, with an estimated 71 million people living with HCV [1, 2] . In the United Kingdom, approximately 200 000 are chronically infected, with 90% of new infections occurring among people who inject drugs (PWID) [3, 4] . Similar epidemics exist in other high-income settings [5] . To reduce the burden of HCV, it is crucial to reduce the incidence of HCV among PWID [6] .
In most settings, needle and syringe programmes (NSPs) are the primary intervention for reducing the transmission of blood-borne viruses among PWID. NSPs provide sterile needles, syringes, injecting equipment and other prevention and support services. There is good evidence that NSPs reduce injecting risk behaviours, and can prevent the acquisition of HCV and HIV among PWID [7] [8] [9] [10] [11] [12] [13] .
Previous research has shown that NSPs are a costeffective intervention to reduce HIV incidence in multiple settings [14] [15] [16] [17] [18] [19] [20] [21] . However, only two studies have considered their cost-effectiveness in reducing HCV incidence [22, 23] , with no studies from western Europe. In the United Kingdom, funding for NSPs is under threat due to budget cuts and shifting emphasis of drug policy to recovery and abstinence-based treatment programmes [24] . To improve the evidence base and inform policy choices, it is therefore important to assess the cost-effectiveness of NSP. We evaluated the cost-effectiveness of current levels of NSP provision on the transmission and disease burden of HCV in three UK settings, compared to a counterfactual of no NSP provision.
METHODS

Setting and intervention
The intervention considered was needle and syringe distribution services to prevent HCV transmission. NSPs in the United Kingdom can be provided through several modalities, including pharmacies, mobile vans or fixed sites. The cost-effectiveness analysis focused on three settings: Bristol, Dundee and Walsall. These settings were selected based on differences in HCV prevalence, access to intervention coverage data and feasibility of conducting a cost-effectiveness analysis. Table 1 summarizes the key attributes of these settings. The chronic prevalence of HCV in the three settings (18-45%) ranges across the UK average of 40% [3] . Coverage of harm reduction interventions varies from 72 to 81% for opioid substitution therapy (OST) and from 30 to 57% for high-coverage needle and syringe provision (HCNSP, taken to be at least one clean needle for every injection) compared with an average of 65% for OST, and from 48 to 77% for HCNSP throughout the United Kingdom [3, 31] . Although data are limited, PWID size estimates across our cities (750-2295) suggest that they have moderate-sized injecting populations [26, 27] .
We collected cost data from NSPs in each area. We only considered needle and syringe distribution to people who inject psychoactive drugs (such as opioids and stimulants; now denoted as PWID), not those injecting image and performance-enhancing drugs (IPEDs), as they have a greater risk of HCV infection [32] . Other services provided by NSPs were not considered, including HCV testing, condom provision and referral to community drug treatment programmes. In addition, we did not consider the impact of NSPs on HIV transmission.
Estimation of costs
The cost-effectiveness analysis uses a UK National Health Service (NHS) (health and social care provider) perspective [33] . We estimated the incremental economic cost of NSP provision in each area for 2013-14 [34] in 2014 pounds sterling (GBP). Cost data collection took place between March 2014 and July 2015 at several sites in each city, including the fixed-site NSP, two randomly selected pharmacy-based NSPs and any additional NSP modalities operating in the area. Costs were estimated for the 2013-14 financial year. We took a bottom-up approach in collecting cost data, first estimating resource use and then valuing those resources according to their opportunity cost [35] . Resource use was measured using direct observation and reviewing programme records. We incorporated all resources: staff salaries, training, equipment, supplies, utilities and building costs. Current market prices (2014 GBP) were applied to all resources; we estimated a 'shadow cost' for volunteer time or subsidized equipment. Overhead and support costs were estimated from programme records, and a portion allocated to NSP provision based on building space and management/support time. Human resource use was estimated through interviews and direct observations. Research costs were not included. All interviewees provided written consent, and the study received ethical approval by the London School of Hygiene and Tropical Medicine Research Ethics Committee (Reference: 6527).
Cost inputs were defined as fixed costs (i.e. do not vary with output) and variable costs (i.e. vary with the level of output). Total costs for 2014 were estimated including all NSP modalities in each area using their total fixed costs, plus an average variable cost for sterile injecting equipment (estimated per needle distributed to PWID).
The costs of HCV care for HCV-related disease came from published estimates for the United Kingdom (Supporting information, Table S1 ) [36, 37] , inflated to 2014 prices [38] . We assumed that HCV treatment delivery costs for people currently injecting were 20% higher than for ex-injectors (extra nurse time) [39] , and assumed treatment with 12-week direct acting anti-viral (DAA) regimens after 2016 [40] at a total drug cost of £39 600 [41] (Supporting information, Table S1 ). We assumed an annual cost for OST [42] .
Model description for estimating impact and cost-effectiveness
A dynamic model of HCV transmission and treatment was developed to estimate the impact of needle and syringe distribution in each city, described elsewhere [10] and in the Supporting information. Briefly, the model incorporates HCV transmission among PWID and disease progression in PWID and ex-injectors. The model is a deterministic compartmental model using ordinary differential equations, stratified by injecting duration, intervention status (OST and/or NSP, or not), risk status (homeless and/or crack injecting or not), currently injecting or not, infection status and disease stage. New initiates to injecting are initially susceptible to HCV and become infected at a per-capita rate depending on their intervention state, injecting duration category, risk category and prevalence of HCV infection in the population. Risk, whether increased (injecting duration and high-risk categories) or decreased (if on OST and HCNSP), is assumed to apply both to HCV transmission and acquisition. We assume random mixing between all subgroups. The model includes HCV disease progression ( Fig. 1 ) [43] . Following successful treatment (sustained viral response), continued slower progression occurs among those with compensated cirrhosis or more severe disease [44] [45] [46] . We account for re-infection among PWID and re-treatment.
Model parameterization and calibration
Epidemiological, demographic and harm reduction-related parameters common to both the intervention and counterfactual scenarios for all three cities are shown in Supporting information, Table S2 . The model was further parameterized for each city using context-specific survey data and data from the literature, and calibrated using intervention coverage and HCV prevalence data in three steps. First, the model was calibrated to PWID population size estimates using a PWID demographic submodel without infection by varying the numbers initiating injecting each year and cessation rates. Secondly, the coverage of HCNSP and OST were fitted using a submodel that includes HCV transmission but no disease progression (allowing recruitment rates onto HCNSP and OST to vary). Thirdly, the HCV prevalence was fitted using the full model with disease progression by varying the transmission rate for those with no increased or decreased risk (see Supporting information for more details). Additional HCV prevalence and incidence data were used to validate the model projections (Supporting information, Tables S2 and S3 and Fig. S1 ). Based on a recent pooled analysis of UK and Australian data, currently being on HCNSP or OST were assumed to reduce the risk of HCV transmission by 41 and 59%, respectively [34] , with the risk reduced multiplicatively for those on OST with HCNSP. Service data on the number of needles and syringes distributed in 2014 were used to estimate the proportion of injections utilizing sterile injecting equipment (coverage) per PWID in each area to proxy the proportion of PWID on HCNSP. Survey data were used to estimate the proportion of PWID currently on OST.
The model was used to estimate the number of new infections and person-years spent in each HCV disease stage. Quality-adjusted life year (QALY) utility weights came from the literature (Supporting information, Table S3 ) [36, 37] , with the baseline quality of life for PWID being lower (0.85) than for other individuals (0.94) [37] .
For 2014, the model directly used the total estimated area-level costs of NSP. For other years, total annual costs were adjusted for changes in the number of PWID while assuming the same NSP cost (inflation-adjusted) and coverage. Costs of HCV care and treatment were attached to each HCV disease stage. We assumed that half of all mild or moderate patients are diagnosed [3] and incur a cost, whereas all individuals in more progressed disease stages incurred care costs. All costs and QALYs were discounted at 3.5% per year [33] .
To reflect parameter uncertainty, distributions were assigned to many model and cost parameters, which were randomly sampled to obtain 1000 model fits (see Supporting information).
Cost-effectiveness analysis
For the NSP intervention scenario we assumed the coverage of HCNSP remained stable for 50 years (2016-65). In contrast, the counterfactual scenario ('no NSP') removed the costs and benefits of HCNSP for 10 years (2016-25), and then re-instated them for 40 years (2026-65) to capture the future effects of the lack of HCNSP on HCV transmission and disease morbidity. A time-horizon of 50 years is standard practice to consider the life-time of individuals impacted by the intervention and to fully capture the effects of HCV disease progression [33] . The incremental costs, disease outcomes and QALYs of NSPs compared to 'no NSPs' were estimated over 2016-65 for all 1000 model fits. Mean incremental costeffectiveness ratios (ICER = incremental costs/incremental effects) were compared to the £20 000 per QALY willingness-to-pay (WTP) threshold recommended by the National Institute for Health and Care Excellence (NICE) [47] . Mean net monetary benefit [NMB = (incremental effectiveness × WTP threshold)-incremental costs] was also estimated for each area. Costeffectiveness acceptability curves were plotted to determine the proportion of simulations that are cost-effective at the WTP threshold.
Sensitivity analysis
We carried out multiple sensitivity analyses to test the impact of assumptions on the ICER. These included assuming: no diagnosis for pre-cirrhotic chronic HCV disease (50% diagnosed in the main analysis); the same HCV treatment cost for people currently and no longer injecting (increased cost for people currently injecting in the main analysis); a 0% discount rate for costs and QALYs (3.5% in the main analysis); and increased time-horizon of 100 years (50 years in the main analysis). A threshold analysis also considered the minimum time-horizon over which NSP are cost-effective at a WTP threshold of £20 000 per QALY. To assess the probable impact of the changing landscape of HCV treatment we conducted analyses assuming 50 or 75% lower cost of HCV treatment from 2016; doubling and quadrupling the low HCV treatment rates in Bristol and Walsall from 2016 (Dundee already has a high treatment rate); and quadrupling the treatment rates in Bristol and Walsall from 2016, while also reducing HCV treatment costs by 75%.
A linear regression analysis of covariance [48] was undertaken to determine which parameter uncertainties contributed most to variability in incremental costs and QALYs.
RESULTS
Cost analysis for NSP
The size and cost of NSPs varied across the areas ( Fig. S2 ).
Impact projections for NSP
Compared to the counterfactual of no NSP over the next 10 years, projections suggest a median of 84-199 infections (8% of infections in Bristol and Walsall, 40% in Dundee) and two to 20 deaths (1% of deaths in each area) would be averted in each area by continuing provision of NSP during this period, with benefits tracked over a further 40 years. Area-level differences in infections averted are due to variations in HCV treatment coverage (greater in Dundee), with wide uncertainty around the impact projections for each area being due to uncertainty in many model parameters, as discussed later. Despite this uncertainty, all simulations projected deaths and infections averted for the NSP intervention scenario (Supporting information, Table S6 ).
Cost-effectiveness analysis
In all three settings, over the 50-year time-horizon, healthcare and treatment costs are lower in the baseline NSP scenario than in the no NSP counterfactual scenario (Supporting information, Table S7 ). Overall, the NSP scenario is cost-saving in Bristol and Dundee, saving an average of £159 712 in Bristol and £2.5 million in Dundee over 50 years and gaining 502 and 195 incremental QALYs, respectively (Table 3 ). In Walsall, the mean incremental cost of the NSP scenario is £114 442 and gains 192 incremental QALYs (ICER £596 per QALY gained). Using a WTP threshold of £20 000 per QALY gained [33] , this represents an NMB of £10.2 million in Bristol, £6.4 million in Dundee and £3.7 million in Walsall over 50 years.
In each city, all simulations suggest the NSP scenario gains QALYs compared with the no NSP scenario. In Dundee, most simulations (78%) suggest that NSP is costsaving; for Bristol and Walsall, 46 and 40% of simulations, respectively, are cost-saving ( Fig. 2 and Supporting information, Fig. S3 ). More than 90% of simulations for each area are below the WTP threshold of £20 000 per QALY saved (Fig. 2) .
Sensitivity analysis
The sensitivity analyses indicated that our costeffectiveness projections are robust to variations in parameter assumptions (Fig. 3) . Increasing the timehorizon to 100 years made the NSP scenario cost-saving in all three cities, as did reducing the discount rate to 0% (costs and QALYs). The threshold analysis revealed that NSP becomes cost-effective in Bristol and Walsall if the time-horizon is longer than 2 or 6 years post-intervention, respectively, while in Dundee it is cost-saving even with no years of follow-up.
The highest ICERs for all three settings occurred when the cost of HCV treatment was reduced by 75% (Bristol and Walsall: £1518 and £2812 per QALY, respectively; Dundee still cost-saving), but the mean ICERs remained well below the WTP threshold. Quadrupling the treatment rate improved the NSP ICER because of an added prevention benefit in terms of reducing re-infections after successful HCV treatment (all three are cost-saving).
Analysis of covariance (Supporting information, Fig.  S4 ) suggests that most of the variability in the incremental costs and QALYs in each setting is due to uncertainty in the efficacy of HCNSP (accounting for 52, 50 and 27% of the variability in incremental costs and 80, 73 and 20% of variability in incremental QALYs in Bristol, Walsall and Dundee, respectively). The more effective HCNSP is at reducing HCV transmission the lower the incremental costs and higher the incremental QALYS (see Supporting information, Fig. S5 for the Bristol example). In Dundee, uncertainty in the prevalence of HCV also caused considerable variability (57% for incremental costs and 61% for incremental QALYs). A higher initial HCV prevalence results in lower incremental costs and higher incremental QALYS resulting in NSP being more cost-effective (see Supporting information, Fig. S5 ). Otherwise, uncertainty in the cost of injecting equipment in Bristol and Walsall was an important cause of variability in incremental costs (10 and 28%, respectively), while uncertainty in the coverage of HCNSP was an important cause of variability in the incremental QALYs for Bristol and Walsall (9 and 5%, respectively).
DISCUSSION
Main findings
Our analyses suggest that NSPs are highly cost-effective in the United Kingdom, and in some settings are cost-saving. We found variation in NSP costs throughout the three areas; there is no 'standard' structure for NSP services in the United Kingdom and, as such, each area had different service modalities and organizational structures. Differences in cost-effectiveness were also driven by variations in the impact achieved; fewest deaths were averted in Walsall due to its lower HCV prevalence [10] , while more deaths and infections were averted in Bristol due to the higher HCV prevalence and larger PWID population. The largest proportion of infections averted was in Dundee, where there is higher coverage of HCV treatment with HCNSP preventing re-infection. These differences did not affect our finding that NSPs are highly cost-effective. Our results were also robust to varied assumptions, including a lower cost for HCV treatment and a scale-up in HCV treatment, both of which are likely to occur in the near future.
Comparison with existing evidence
This is the first study, to our knowledge, evaluating the cost-effectiveness of NSPs in western Europe, and the first ever study to use empirical estimates of the efficacy of NSP for reducing HCV transmission risk [9] . Two other studies have considered the cost-effectiveness of NSP for averting HCV transmission; a study from Baltimore [22] estimated a cost of several hundred thousand dollars per averted HCV infection, and an Australian study indicated that NSPs are cost-saving in preventing HIV and HCV infection due to averted health-care costs [23] . Unfortunately, it is difficult to compare these findings to our projections. The US study did not collect primary cost data, but assumed a cost of US$5 per NSP client per day, contrasting with our estimates of £0.16-0.42 per PWID per day. The results of the Australian analysis were driven by the reduction in HIV transmission, which we did not include in our analysis.
Strengths and limitations
A strength of our analysis lies in our use of primary cost data to reflect the 'real-world' costs of implementing NSPs in the United Kingdom. Although this ensures their relevance to the United Kingdom, uncertainties still existed due to gaps in the data. This was especially true for pharmacy-based NSP services, where detailed records were not available. These uncertainties in the cost of NSPs were included in our projections, and our findings were robust (i.e. were all cost-effective) despite this. Standardized reporting of number of visits and numbers of needles and syringes distributed would facilitate comparison across different NSP sites, while implementing a system to record the number of individual clients reached would greatly facilitate estimation of unit costs and intervention coverage.
A second potential weakness is that the assessment of health impact is based on model projections rather than study outcomes, and so caution is advised in the interpretation of our cost-effectiveness findings. This is common to all NSP evaluations, with our study improving on previous analyses by using empirical effect estimates for how NSP reduces HCV transmission risk rather than relying upon self-reported behaviour change. We incorporated uncertainty in these empirical effect estimates in our analysis, as well as other parameters, which contributed to the large variation in both incremental costs and QALYs. For more information on derivation see Supporting information and [34] ; NSP = needle and syringe programme; PWID = people who inject drugs; GBP = pounds sterling.
Uncertainty in the HCV prevalence in Dundee also contributed to the variation in incremental costs and QALYs in that setting. Despite this uncertainty our results were robust, with more than 90% of simulations under the UK WTP of £20 000 per QALY. Thirdly, there was uncertainty in the NSP coverage for each area. We used conservative service provision estimates of NSP coverage, which were lower or comparable to survey estimates from each setting, and also included uncertainty around these coverage estimates. More accurate estimates of syringe coverage are needed, as is consistent monitoring of NSPs and the services they provide [12] .
Our approach to estimating the cost-effectiveness of NSPs was highly conservative: we did not incorporate other potential health benefits of NSP or impact upon people injecting IPEDs. We did not incorporate the health benefits associated with NSPs reducing the risk of HIV acquisition [49] because of difficulty in reliably modelling the transmission of an infection that is at low levels. Incorporating HIV infections averted would improve our costeffectiveness estimates [15, 50] . The analysis also did not include the health benefits from reducing injection-site infections and injuries [51] , which may result from engaging the client in discussions about safer injecting behaviour. Our analysis also did not reflect the potential impact of NSPs in addressing the complex mental health and social support issues that PWID experience [52, 53] . When considering other potential benefits of NSPs, such as preventing HIV infection or skin and soft tissue infections, and addressing the psychosocial and welfare needs of PWID, NSPs are likely to be highly cost-saving.
Implications and conclusions
NSP services are a highly effective low-cost intervention to reduce HCV transmission, and in some settings are costsaving. For example, in Dundee, we estimate long-term savings of up to 250% of the initial investment. In a recent analysis of public health interventions considered by NICE between 2006 and 2010, only 15% were cost-saving QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; NSP = needle and syringe programme; GBP = pounds sterling. Figure 2 Cost-effectiveness acceptability curves for each city [54] . In this context, NSPs can be considered a very strong investment choice. These findings clearly point to the need to maintain funding for NSP services in the United Kingdom and elsewhere-while at the same time emphasizing the need to strengthen the evidence for their effectiveness, including how the level of NSP provision and other NSP characteristics affect its efficacy. Further work should also investigate what strategies or factors improve the cost-effectiveness of NSP and what can aid its scale-up. The findings also highlight the importance of joint commissioning and decisionmaking between agencies in the United Kingdom to meet the needs of local populations. Due to recent NHS reforms, the agencies responsible for commissioning NSPs are often different from those incurring any cost-savings. A cofinancing approach would represent the overall societal benefits of such an investment more accurately [55] . Different agencies may also need outcomes on different timeframes; a life-time horizon is recommended in NICE guidance for economic evaluations, while policymakers and funders are more concerned with short-term outcomes. We found that shorter time-horizons remained costeffective in Bristol and Walsall (after 2 and 6 years of follow-up) and cost-saving in Dundee. Short-term returns may also be accrued through psychosocial and welfare benefits of NSPs, as mentioned above.
These findings, while having limited generalizability for low-and middle-income countries, are likely to be highly generalizable to other high-income settings with comparable HCV prevalence and harm reduction coverage, such as Australasia and western Europe [56] , and therefore support the recommendations of the World Health Organization to develop and implement policies to support harm reduction among PWID [57] . These interventions should be delivered in combination with and complemented by prioritization of drug treatment and expansion of HCV and HIV treatment [24] . 
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